GLP1R and cardiac transplant: Reported safety data were limited, as available observational studies did not identify a consistent short-term signal of harm associated with immunosuppression management or graft outcomes.<h4>Conclusions</h4>GLP-1 RA therapy was associated with improved weight- and glycemia-related outcomes in adult heart transplant recipients.